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immunoreactivity in the frontal cortex in patients
with frontal lobe dementia of non-Alzheimer type
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Abstract
The morphology and distribution of
local-circuit neurons (interneurons)
were examined, by calbindin D-28k and
parvalbumin immunocytochemistry, in
the frontal cortex (area 8) in two patients
with frontal lobe dementia of non-
Alzheimer type associated with classical
amyotrophic lateral sclerosis (ALS), and
in seven normal cases. The density of
calbindin D-28k immunoreactive cells
was dramatically reduced in ALS
patients, but the density of parvalbumin-
immunoreactive neurons was preserved.
Decreased density of calbindin D-28k-
immunoreactive neurons, which are
mainly located in the upper cortical lay-
ers, may interfere with the normal pro-
cessing of cortico-cortical connections,
whereas integrity of parvalbumin-
immunoreactive cells may be associated
with the preservation of the major
inhibitory intracortical circuits in
patients with frontal lobe dementia.
(_ Neurol Neurosurg Psychiatry 1993;56:257-261)
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Intellectual impairment and dementia occur
in some patients with classic amyotrophic lat-
eral sclerosis (ALS; motor neuron disease).1-8
Clinical symptoms and signs conform with
different prefrontal syndromes,9 whereas mor-
phological lesions are characterised by atro-
phy of the frontal (and temporal) lobes,
neuron loss and spongiosis in layers II and
III, together with gliosis of the cerebral cor-
tex, and myelin pallor and gliosis of the sub-
cortical white matter. These abnormalities are
similar in frontal lobe dementia of non-
Alzheimer type in older people.10-2
Golgi studies have shown degeneration of
pyramidal and non-pyramidal (local-circuit)
neurons in layers II and III,'13 which suggest
that, in addition to neuron loss, abnormalities
of surviving cells in the frontal cortex may
contribute to the pathology in patients with
frontal lobe dementia.
In this study we investigate the vulnerabili-
ty of different types of intracortical local-cir-
cuit neurons by means of parvalbumin and
calbindin immunocytochemistry in two
patients with mental deterioration and
dementia associated with ALS. We chose this
method because calbindin D-28k and parval-
bumin are calcium-binding proteins which
are found in the cerebral cortex and hip-
pocampus in different populations of local-
circuit neurons which use gamma-aminobu-
tyric acid (GABA) as a neurotransmitter.14-24
Patients and methods
The patients were two women aged 38 and
71 years. Both conformed to previous clinical
descriptions of dementia associated with
AM. 1-8 1325
The patients died as a result of bilateral
bronchopneumonia 4 and 2 months, respec-
tively, from the beginning of the motor signs.
The brains were removed less than 6 hours
(first case) and 2 hours (second case) after
death, immediately fixed in fresh 5% formalin
(first case) or 4% paraformaldehyde (second
case) for about four weeks, and later
processed for microscopical examination fol-
lowing currently used neuropathological
methods. The neuropathological findings
were similar in both patients and included
marked neuron loss, gliosis and chromatolysis
of the remaining nerve cells in the hypoglossal
nucleus, demyelination of the pyramidal
tracts at the level of the bulbar pyramids and
degeneration of layer V pyramidal cells in the
motor cortex. In addition, the frontal lobes
were atrophic due to nerve cell loss and spon-
giosis in layers II and III, together with
reduction of the subcortical white matter.
Astrocytic gliosis in the cerebral cortex and
white matter of the frontal (and temporal)
lobes were found. Cortical lesions were more
severe in the first patient.
Neurofibrillary degeneration, senile
plaques, and granulovacuolar degeneration
were not seen. Pick bodies were absent, and
Lewy bodies were not observed in the sub-
stantia nigra and cerebral cortex.
Intraneuronal argyrophilic grains were not
found in the cerebral cortex and hippocam-
pus.
Samples of the left frontal lobe cerebral
cortex were obtained on the second day of
fixation, protected with 30% saccharose,
frozen and stored at - 80°C until use.
Control specimens were from seven
patients aged 19-77 years mean (SD) 46
(21 *5) with no neurological, metabolic or
malignant disease. Technical procedures to
minimise methodological pitfalls, including
short interval between death and tissue pro-
cessing, use of fresh fixative solutions, and
reduction of the time of fixation for immuno-
cytochemistry to 48 hours, were similar in
ALS patients and controls.
Sections 50,u thick were obtained with a
freezing microtome and processed free-float-
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Figure I Calbindin D-
28k-immunoreactive
neurons in the frontal
cortex (area 8) in one
control (A and B), and in
two patients with
intellectual impairment
associated with ALS (C
and D). Decreased
immunoreactivity (lower
numbers of neurons and
reduced dendritic arbors)
are observed in these
patients. A and B: control
aged 68years; C: second
case; D: first case. MOL:
molecular layer; II, III:
cellular layers. A-C: bar =
20011; B, bar = 100,u.
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counted in ten vertical columns 1200 , wide
from the whole cortical thickness in the
crown of area 8 in every case, and their mean
(SD) densities were expressed per mm.2
Results
Calbindin D-28k-immunoreactive cells were
small multipolar neurons with ascending den-
drites in the molecular layer, and small bituft-
ed cells and double bouquet neurons in layers
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Figutre 2 Parvalbunnil-
ininunoreactive nieuironis in
the fronital cortex (area 8)
ini onie conitrol (aged 68
years) (A) atnd in onie
patienit with demlentia
associated with ALS (case
I) (B). PARV
inununloreactivity is
preserved in the patient
with dementia. III-VI:
celluilar layers III- VI. Bar
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II and III (fig 1 A and B). Small numbers of
immunolabelled cells, most of them multipo-
lar, were also seen in layers V and VI.
Pyramidal cells were only very weakly
immunolabelled in layers II and III.
Homogeneous labelling of pyramidal and
non-pyramidal neurons in these layers did
occur, however, when the primary antibody
was used at dilutions lower than those
described in Methods.
Calbindin D-28k immunoreactivity was
drastically reduced in the two patients with
ALS and mental impairment (fig 1 C and D).
The number of immunolabelled neurons was
decreased, and most of the remaining neu-
rons had very short immunoreactive dendritic
arbors. Significant differences in the density
of calbindin D-28k-immunoreactive cells
were found between patients with dementia
and controls (ALS patients with dementia:
22-4 (9 1) cells per mm2; controls: 68-5 (9-1);
Mann Whitney U test, 2-tailed p < 0.001).
Parvalbumin-immunoreactive cells were
multipolar neurons found in all cortical layers
except the molecular layer, and predominat-
ing in layers III, IV and V. Parvalbumin
immunoreactivity was preserved in patients
with ALS, and the morphology and distribu-
tion of parvalbumin-immunolabelled cells
were similar in ALS patients and controls (fig
2 A and B). Furthermore, quantitative studies
disclosed no significant differences in the
density of parvalbumin-immunoreactive cells
between ALS patients with dementia and
controls (110-8 (19-3) and 93-6 (14-6) cells
per mm2 respectively; p > 0 1 Mann-Whitney
U test).
~~~ p~~~
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Discussion
The morphology and distribution of cal-
bindin D-28k-immunoreactive cells in the
present series are similar to those described in
other observations.'1'82426-29 However, in con-
trast to the temporal lobe,'9 multipolar neu-
rons of layer II with very long descending
dendrites and horizontal neurons of the mole-
cular layer were not labelled in the frontal
cortex, suggesting that calbindin D-28k
immunoreactivity in the human neocortex is
subject to regional variations.
Parvalbumin-immunoreactive neurons in
this study were similar to basket neurons and
chandelier cells previously described in the
neocortex and hippocampus. 16 28 334
The density of calbindin D-28k-immuno-
reactive neurons was reduced in ALS
patients, but the density of parvalbumin-
immunoreactive neurons was preserved.
Although our quantitative data do not take
into account the cortical atrophy which could
lead to a compacting down of surviving cells,
this probably does not affect the outcome of
the comparisons between ALS patients and
controls. On the contrary, because of cortical
atrophy the density of cells in ALS with
dementia will be artificially raised, and, for
this reason, the degree of actual loss of cal-
bindin D-28k-immunoreactive cells is under-
estimated in our patients.
Whether loss of immunoreactivity reflects a
reduction in the number of neurons cannot
be assessed on the basis of the immunocyto-
chemical data alone. Nissl preparations, how-
ever, demonstrate loss of neurons in the
upper layers. This feature together with the
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observation of degenerated pyramidal and
non-pyramidal cells in the upper layers, as
seen with the Golgi method,'3 points to the
likelihood that loss of calbindin D-28k
immunoreactivity is related to an actual loss
of neurons.
Although not universally accepted,"5 simi-
lar findings are found in the neocortex of
most patients with Alzheimer's disease in
which calbindin D-28k immunoreactivity is
decreased whereas parvalbumin immunoreac-
tivity is preserved.""-9 Parvalbumin immuno-
reactivity is, however, decreased in a number
of patients with, probably, very advanced
Alzheimer's disease.38 40 41
Together, these observations indicate that
vulnerability of local-circuit neurons in
frontal lobe dementia, and in Alzheimer's dis-
ease, might depend on the calcium-binding
protein content, and that the presence of par-
valbumin in neurons seems to decrease their
susceptibility to neuro-degeneration, as
already pointed out in the kindling model of
epilepsy.42 Although this latter possibility is
still highly speculative, it is worth noting that
parvalbumin-immunoreacrive cells in the hip-
pocampus are also resistant to ischaemia.43
However, as parvalbumin-immunoreactive
neurons seem to be in deeper layers and the
pathology is most marked in layer II, it is pos-
sible that no selective neuronal damage, on
the basis of differential calcium-binding pro-
tein content, occurs in ALS patients with
dementia. Calbindin D-28k-immunoreactive
neurons could be more affected simply
through anatomical considerations.
On the basis of their typology and distribu-
tion in layers II and III, which are the main
source and the main recipient of cortico-cor-
tical projections," we propose that decreased
numbers of calbindin D-28k-immunoreactive
local-circuit neurons in the neocortex may
interfere with the operations of contralateral
and ipsilateral cortico-cortical connections.
These abnormalities may contribute to the
development of neurological deficits.
On the other hand, since fast-spiking cells
in rat hippocampus contain parvalbumin,45
and basket neurons and chandelier cells
(which are the main parvalbumin-containing
neurons in the neocortex and hippocampus)
establish synapses with the perikaryon and
proximal segment of the axon pyramidal
cells,4647 it is feasible that these neurons are
the most potent inhibitory cells of the cere-
bral cortex. Preservation of parvalbumin-
immunoreactive cells therefore may be
associated with the preservation of the major
inhibitory circuits in the neocortex in patients
with frontal lobe dementia.
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